Our aim is to evaluate the safety, efficacy, predictability, and clinical outcome of femtosecond laser–assisted in situ keratomileusis (FS-LASIK) procedures performed on the day of the initial consultation relative to procedures performed at subsequent visits.
A retrospective cohort study design was used. The study group included patients with myopia of different severities who were treated with FS-LASIK in 2013 through 2014 in an optical outpatient clinic of a large private medical service. Inclusion criteria were at least 18 years of age, a stable refraction for 12 months, no history of autoimmune disease, ocular surgery, or eye disease, and complete medical records. Background, clinical, and outcome data were collected from the patient files.
Femtosecond laser–assisted in situ keratomileusis was performed in 80 patients (160 eyes) at the first visit and 361 patients (719 eyes) at a subsequent visit. The mean±SD spherical equivalent (SE) refraction before surgery was −3.74±2.03 D in the first-visit group and −3.73±1.87 D in the subsequent-visit group (P=0.99). Efficacy index values were 0.97±0.15 in the first-visit group and 0.98±0.13 in the subsequent-visit group (P=0.92), and corresponding safety index values were 0.99±0.15 and 0.99±0.12 (P=0.81). The final SE measured −0.09±0.58 D in the first-visit group and −0.19±0.55 D in the subsequent-visit group (P=0.05). Types and rates of complications were similar in the two groups.
There is no significant difference in the results of refractive surgery with FS-LASIK between procedures performed at the initial or subsequent visits. In both conditions, FS-LASIK surgery is associated with excellent safety, efficacy, and predictability profiles.
Assuta Optic (A.G., E.L., I.B.), Assuta Medical Center, Tel Aviv, Israel; Ophthalmology Division (A.G., O.R., E.L., R.E., I.B.), Rabin Medical Center, Petach Tikva, Israel; Department of Ophthalmology (M.M., R.E.), Rambam Health Care Campus, Haifa, Israel; and Sackler Faculty of Medicine (E.L., I.B.), Tel Aviv University, Tel Aviv, Israel.
Address correspondence to Irit Bahar, M.D., M.H.A., Ophthalmology Division, Rabin Medical Center, 39 Jabotinski Street, Petah Tikva 49100, Israel; e-mail: firstname.lastname@example.org
The authors have no funding or conflicts of interest to disclose.
Accepted March 31, 2019